Recent advancements in lung cancer treatment are offering new hope, especially for those with advanced or hard-to-treat cases. Scientists are developing highly targeted drugs that focus on the unique features of each person’s cancer. These treatments aim to attack only the cancer cells—sparing healthy ones—and may reduce side effects while helping patients live longer. New tools like antibody-drug conjugates (ADCs) and bispecific antibodies are leading the way, with some early results showing success even in cases where standard chemo and immunotherapy haven’t worked well.
Some of these new drugs target specific proteins found in certain lung cancers, including those seen in both non-small cell (NSCLC) and small cell lung cancer (SCLC). Researchers are also exploring ways to combine immune-based therapies with these new targeted drugs to overcome resistance and keep the cancer from returning. While many of these treatments are still in early testing, they represent a major step toward more personalized—and more hopeful—options for lung cancer patients. (Source: Drug Target Review)
